Roth Capital 'Encouraged' by PoC Data from Celldex's (CLDX) Varlilumab Phase 1
Tweet Send to a Friend
Roth Capital affirms Celldex Therapeutics (Nasdaq: CLDX) at Buy with a price target of $40 after the company presented a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
